- Home
- WVE
as of 02-13-2026 3:46pm EST
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
| Founded: | 2012 | Country: | Singapore |
| Employees: | N/A | City: | SINGAPORE |
| Market Cap: | 2.4B | IPO Year: | 2015 |
| Target Price: | $30.44 | AVG Volume (30 days): | 3.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 16 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.74 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.28 - $21.73 | Next Earning Date: | 03-03-2026 |
| Revenue: | $109,230,000 | Revenue Growth: | 103.75% |
| Revenue Growth (this year): | -60.3% | Revenue Growth (next year): | 16.10% |
| P/E Ratio: | N/A | Index: | N/A |
| Free Cash Flow: | -198170000.0 | FCF Growth: | N/A |
AI-Powered WVE Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Wave Life Sciences Ltd. (WVE)
See Remarks
Avg Cost/Share
$13.45
Shares
1,883
Total Value
$25,326.35
Owned After
61,867
SEC Form 4
President and CEO
Avg Cost/Share
$13.45
Shares
10,480
Total Value
$140,956.00
Owned After
275,520
SEC Form 4
Chief Financial Officer
Avg Cost/Share
$13.45
Shares
3,588
Total Value
$48,258.60
Owned After
134,385
SEC Form 4
See Remarks
Avg Cost/Share
$13.45
Shares
3,228
Total Value
$43,416.60
Owned After
408,246
SEC Form 4
See Remarks
Avg Cost/Share
$16.31
Shares
9,375
Total Value
$150,260.10
Owned After
61,867
Chief Financial Officer
Avg Cost/Share
$20.14
Shares
50,036
Total Value
$1,001,979.00
Owned After
134,385
Director
Avg Cost/Share
$14.40
Shares
93,445
Total Value
$1,369,323.75
Owned After
12,700
Director
Avg Cost/Share
$15.00
Shares
42,000
Total Value
$630,000.00
Owned After
12,700
SEC Form 4
See Remarks
Avg Cost/Share
$14.66
Shares
441,031
Total Value
$6,427,084.96
Owned After
61,867
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Francis Chris | WVE | See Remarks | Feb 9, 2026 | Sell | $13.45 | 1,883 | $25,326.35 | 61,867 | |
| BOLNO PAUL | WVE | President and CEO | Feb 9, 2026 | Sell | $13.45 | 10,480 | $140,956.00 | 275,520 | |
| Moran Kyle | WVE | Chief Financial Officer | Feb 9, 2026 | Sell | $13.45 | 3,588 | $48,258.60 | 134,385 | |
| Vargeese Chandra | WVE | See Remarks | Feb 9, 2026 | Sell | $13.45 | 3,228 | $43,416.60 | 408,246 | |
| Francis Chris | WVE | See Remarks | Jan 2, 2026 | Sell | $16.31 | 9,375 | $150,260.10 | 61,867 | |
| GSK plc | WVE | 10% Owner | Dec 11, 2025 | Buy | $19.00 | 1,470,000 | $27,930,000.00 | 18,245,691 | |
| Moran Kyle | WVE | Chief Financial Officer | Dec 9, 2025 | Sell | $20.14 | 50,036 | $1,001,979.00 | 134,385 | |
| HENRY CHRISTIAN O | WVE | Director | Dec 8, 2025 | Sell | $14.40 | 93,445 | $1,369,323.75 | 12,700 | |
| Rawcliffe Adrian | WVE | Director | Dec 8, 2025 | Sell | $15.00 | 42,000 | $630,000.00 | 12,700 | |
| Francis Chris | WVE | See Remarks | Dec 8, 2025 | Sell | $14.66 | 441,031 | $6,427,084.96 | 61,867 |
Compare WVE vs Leading Stocks
See how WVE stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "WVE Wave Life Sciences Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.